260 related articles for article (PubMed ID: 33185628)
1. Amifampridine to treat Lambert-Eaton myasthenic syndrome.
Oh SJ
Drugs Today (Barc); 2020 Oct; 56(10):623-641. PubMed ID: 33185628
[TBL] [Abstract][Full Text] [Related]
2. Amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndrome.
Mantegazza R
Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1013-1018. PubMed ID: 31639317
[No Abstract] [Full Text] [Related]
3. Amifampridine for the treatment of Lambert-Eaton myasthenic syndrome.
Oh SJ
Expert Rev Clin Immunol; 2019 Oct; 15(10):991-1007. PubMed ID: 31533480
[No Abstract] [Full Text] [Related]
4. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine.
Lindquist S; Stangel M
Neuropsychiatr Dis Treat; 2011; 7():341-9. PubMed ID: 21822385
[TBL] [Abstract][Full Text] [Related]
5. Amifampridine for the Management of Lambert-Eaton Myasthenic Syndrome: A New Take on an Old Drug.
Yoon CH; Owusu-Guha J; Smith A; Buschur P
Ann Pharmacother; 2020 Jan; 54(1):56-63. PubMed ID: 31319693
[No Abstract] [Full Text] [Related]
6. Neuromuscular junction disorders beyond myasthenia gravis.
Oh SJ
Curr Opin Neurol; 2021 Oct; 34(5):648-657. PubMed ID: 34914667
[TBL] [Abstract][Full Text] [Related]
7. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
Schoser B; Eymard B; Datt J; Mantegazza R
J Neurol; 2017 Sep; 264(9):1854-1863. PubMed ID: 28608304
[TBL] [Abstract][Full Text] [Related]
8. 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.
Molgó J; Guglielmi JM
Pflugers Arch; 1996; 431(6 Suppl 2):R295-6. PubMed ID: 8739381
[TBL] [Abstract][Full Text] [Related]
9. [P/Q-type Calcium Channel Antibodies in Lambert-Eaton Myasthenic Syndrome].
Kitanosono H; Shiraishi H; Motomura M
Brain Nerve; 2018 Apr; 70(4):341-355. PubMed ID: 29632282
[TBL] [Abstract][Full Text] [Related]
10. Lambert-Eaton myasthenic syndrome.
Newsom-Davis J
Rev Neurol (Paris); 2004 Feb; 160(2):177-80. PubMed ID: 15034474
[TBL] [Abstract][Full Text] [Related]
11. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
Wirtz PW; Titulaer MJ; Gerven JM; Verschuuren JJ
Expert Rev Clin Immunol; 2010 Nov; 6(6):867-74. PubMed ID: 20979551
[TBL] [Abstract][Full Text] [Related]
12. Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.
Oh SJ; Shcherbakova N; Kostera-Pruszczyk A; Alsharabati M; Dimachkie M; Blanco JM; Brannagan T; Lavrnić D; Shieh PB; Vial C; Meisel A; Komoly S; Schoser B; Sivakumar K; So Y;
Muscle Nerve; 2016 May; 53(5):717-25. PubMed ID: 26852139
[TBL] [Abstract][Full Text] [Related]
13. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
Quartel A; Turbeville S; Lounsbury D
Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
[TBL] [Abstract][Full Text] [Related]
14. Lambert-Eaton myasthenic syndrome in a young girl.
Moor SE; Gardin T
BMJ Case Rep; 2022 Feb; 15(2):. PubMed ID: 35228217
[TBL] [Abstract][Full Text] [Related]
15. Lambert-Eaton Myasthenic Syndrome.
Kesner VG; Oh SJ; Dimachkie MM; Barohn RJ
Neurol Clin; 2018 May; 36(2):379-394. PubMed ID: 29655456
[TBL] [Abstract][Full Text] [Related]
16. Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy.
Hülsbrink R; Hashemolhosseini S
Clin Neurophysiol; 2014 Dec; 125(12):2328-36. PubMed ID: 25065299
[TBL] [Abstract][Full Text] [Related]
17. 3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials.
Zhang N; Hong D; Ouyang T; Meng W; Huang J; Li M; Hong T
BMC Neurol; 2021 Sep; 21(1):371. PubMed ID: 34563155
[TBL] [Abstract][Full Text] [Related]
18. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.
Sanders DB; Juel VC; Harati Y; Smith AG; Peltier AC; Marburger T; Lou JS; Pascuzzi RM; Richman DP; Xie T; Demmel V; Jacobus LR; Aleš KL; Jacobus DP;
Muscle Nerve; 2018 Apr; 57(4):561-568. PubMed ID: 29280483
[TBL] [Abstract][Full Text] [Related]
19. Treatment for Lambert-Eaton myasthenic syndrome.
Keogh M; Sedehizadeh S; Maddison P
Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260
[TBL] [Abstract][Full Text] [Related]
20. Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist.
Tarr TB; Lacomis D; Reddel SW; Liang M; Valdomir G; Frasso M; Wipf P; Meriney SD
J Physiol; 2014 Aug; 592(16):3687-96. PubMed ID: 25015919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
